Intellicell Biosciences, Inc. (OTC: SVFC) Sub Penny Stock to Watch!

SVFC is a Sub Penny Stock on Watch!

Intellicell Biosciences, Inc. (OTC: SVFC) has seen a massive increase in trading volume in recent weeks after the stock hit an all-time low of $0.0012. Investors are speculating that this was the stocks reversal point and its nothing but green sky's ahead as SVFC has a huge gap to fill from here.

SVFC is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. The Company has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

According to some there is a massive demand for this Stem Cell technology and the major Orthopedic Sports Doctors have long known that the stem cells from fat, which is really soup cells from the blood vessels of the fat, would become the greatest sports medicine in the world. Up until recently sports players went oversees and to the Caribbean and Latin America to be treated because of the success of the use of these multi potent cells including Bartolo Colon and several others. Because of IntelliCell's invention, people can now receive this medicine in the United States.

OTCMAGIC HAS A MONSTER PICK COMING! (Subscribe right now)

At the beginning of November SVFC announced that it has supplied its cellular product, stromal vascular fraction cells for the successful treatment of a patient with Multiple Sclerosis.

The pr goes on to say that "It is important to note that by "successful," the company is declaring that these cells do not cure Multiple Sclerosis, but of the 19 patients with MS that ReGen Medical has treated using IntelliCell's technology, each have gained anywhere from good to significant quality of life improvements.

Dr. Steven Victor, CEO of IntelliCell Biosciences, commented, "The patient mentioned in this release, was the first clinical case we treated for MS with IntelliCell's SVFC technology. If not for our beneficial treatments, this patient would be restricted to a wheelchair and lose total sight in one of her eyes. Previously, this patient had been unsuccessfully treated at some of the most respected Medical Centers in the country and received little or no improvement to her symptoms. By utilizing IntelliCell's paradigm shifting medical solutions, we have dramatically improved the quality of this patient's life. IntelliCell is confident that the future of medicine will entail utilizing cellular therapy for previously unmet clinical needs, and we expect to establish ourselves as a market leader in this emerging industry."

Conclusion: SVFC has seen some important developments in recent weeks that make this both a really exciting story and possibly an excellent trade opportunity in the coming weeks and months. The stock recently hit an all-time low of $0.0012 coupled with a massive increase in trading volume. While SVFC is very cheap here they are quickly developing the type of loyal following that can catapult these subs to record gains. The Stem Cell Sector is a sector responsible for many highly explosive moves in the past.

To find out the inside scoop on SVFC subscribe to OTCMagic.com right now. Also everyone should know, we have something HUGE coming!

 
Intellicell Biosciences, Inc.
Steven Victor
Robert J. Sexauer
intellicellbiosciences.com
 
STOCK INFORMATION
SYMBOL: OTC: SVFC
Shares Outstanding NA
Market Cap: NA
 
Intellicell Biosciences, Inc. (OTC: SVFC) was formed under the name Regen Biosciences, Inc. on August 13, 2010 as a pioneering regenerative medicine company to develop and commercialize regenerative medical technologies in large markets with unmet clinical needs.  On February 17, 2011, Regen Biosciences, Inc. changed its name to IntelliCell BioSciences Inc. To date, IntelliCell has developed proprietary technologies that allow for the efficient and reproducible separation of stromal vascular fraction containing adipose stem cells that can be performed in tissue processing centers and in doctors’ offices.

Comments are closed.

Trade U.S. Stocks with

Scottrade TD Ameritrade E*Trade Securities ShareBuilder Charles Schwab